Replies to post #112356 on Biotech Values

[DewDiligence]

HCV is not PPHM’s only interest...nor is any one type of cancer. They think they have a broad spectrum anti-cancer and anti-viral Mab in Bavituximab.

Throughout history, when a drug has been purported to work against multiple cancers and multiple unrelated viruses, the drug in question has usually ended up working well against nothing in particular. Something for you to bear in mind while you try to ascertain whether PPHM’s claims for Bavituximab are credible.

At this juncture, I rate the probability of Bavituximab success in HCV to be infinitesimal, so it does not even warrant inclusion in the bottommost paragraph of the “HCV: Most Likely to Succeed” compilation in #msg-58518317.